Forty Seven Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Forty Seven Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C2810
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Forty Seven Inc (Forty Seven), formerly CD47 Sciences Inc is a clinical-stage immuno-oncology company that focuses on the development of therapies to treat cancer. The company’s lead molecule Hu5F9-G4 is a monoclonal antibody that is used against the CD47 receptor. Its monoclonal antibody is evaluated in four phase 1 clinical studies in patients with solid tumors or cutaneous T-cell lymphoma, acute myeloid leukemia, non-Hodgkin’s lymphoma, myelodysplastic syndrome and colorectal carcinoma across the US and the UK. The company partners with biotechnology and pharmaceutical companies. Forty Seven is headquartered in Menlo Park, California, the US.

Forty Seven Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Forty Seven Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Forty Seven Inc, Medical Devices Deals, 2012 to YTD 2018 9
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Forty Seven Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Forty Seven Raises USD75 Million in Series B Financing 11
Forty Seven Raises USD75 Million in Series A Venture Financing 12
Partnerships 13
Forty Seven Enters into Agreement with Merck 13
Forty Seven Enters into Agreement with Genentech 14
Licensing Agreements 15
Forty Seven Enters into Licensing Agreement with Stanford University 15
Equity Offering 16
Forty Seven Prices IPO of Shares for USD112.5 Million 16
Forty Seven Inc – Key Competitors 18
Forty Seven Inc – Key Employees 19
Forty Seven Inc – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Corporate Communications 21
Apr 30, 2018: Forty Seven Names Ian T. Clark As Board Director 21
Apr 03, 2018: Forty Seven Appoints Ann D. Rhoads as Chief Financial Officer 22
Feb 20, 2018: Forty Seven Appoints Kristine M. Ball to Board of Directors 23
Mar 20, 2017: Forty Seven Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st 24
Product News 25
12/06/2017: Forty Seven Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia 25
04/05/2017: The Leukemia & Lymphoma Society Expands its Innovative Therapy Acceleration Program with a Novel Immunotherapy for Lymphoma Patients 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Forty Seven Inc, Pharmaceuticals & Healthcare, Key Facts 2
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Forty Seven Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Forty Seven Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Forty Seven Inc, Medical Devices Deals, 2012 to YTD 2018 9
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Forty Seven Raises USD75 Million in Series B Financing 11
Forty Seven Raises USD75 Million in Series A Venture Financing 12
Forty Seven Enters into Agreement with Merck 13
Forty Seven Enters into Agreement with Genentech 14
Forty Seven Enters into Licensing Agreement with Stanford University 15
Forty Seven Prices IPO of Shares for USD112.5 Million 16
Forty Seven Inc, Key Competitors 18
Forty Seven Inc, Key Employees 19

List of Figures
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Forty Seven Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Forty Seven Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Syndax Pharmaceuticals Inc (SNDX):企業の財務・戦略的SWOT分析
    Summary Syndax Pharmaceuticals Inc (Syndax) is a biopharmaceutical company that develops and commercializes therapies for multiple cancer indications. The company’s lead product candidate includes entinostat, an oral, small molecule drug candidate, which is in phase 3 clinical trial used for the tre …
  • Sino Hotels (Holdings) Limited:企業の戦略・SWOT・財務分析
    Sino Hotels (Holdings) Limited - Strategy, SWOT and Corporate Finance Report Summary Sino Hotels (Holdings) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Thomson Reuters Corporation:企業のM&A・事業提携・投資動向
    Thomson Reuters Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Thomson Reuters Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Suburban Propane Partners LP (SPH):企業の財務・戦略的SWOT分析
    Summary Suburban Propane Partners LP (Suburban Propane) distributes and markets energy-related products. The company supplies propane, fuel oil and refined fuels, and markets natural gas and electricity in deregulated markets. It also provides installation and service of various types of whole-house …
  • First Philippine Holdings Corp (FPH):企業の財務・戦略的SWOT分析
    First Philippine Holdings Corp (FPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Dr. August Oetker KG:戦略・SWOT・企業財務分析
    Dr. August Oetker KG - Strategy, SWOT and Corporate Finance Report Summary Dr. August Oetker KG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • SS&C Advent:企業の戦略的SWOT分析
    SS&C Advent - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Dassault Systemes SE (DSY):企業の財務・戦略的SWOT分析
    Dassault Systemes SE (DSY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Cerner Corp (CERN):医療機器:M&Aディール及び事業提携情報
    Summary Cerner Corp (Cerner) is a provider of healthcare information technology and related services. It offers a comprehensive range of solutions and services which assist the clinical, financial and operational needs of organizations. The company’s major solutions include extended care solutions; …
  • Ellex Medical Lasers Limited (ELX):企業の財務・戦略的SWOT分析
    Ellex Medical Lasers Limited (ELX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Alviva Holdings Ltd (AVV):企業の財務・戦略的SWOT分析
    Alviva Holdings Ltd (AVV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Microbion Corp-製薬・医療分野:企業M&A・提携分析
    Summary Microbion Corp (Microbion) is a clinical stage biopharmaceutical company which develops therapeutic products. The company develops products for the treatment of antibiotic-resistant infections and control of microbial biofilms. It develops environmentally responsible solutions to prevent mic …
  • Arsenal Holdings plc:企業の戦略的SWOT分析
    Arsenal Holdings plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Fast Track Diagnostics Ltd.:医療機器:M&Aディール及び事業提携情報
    Summary Fast Track Diagnostics Ltd. (Fast Track) is engaged in designing, manufacturing and supplying of infectious disease detection kits. It offers Real Time PCR multiplexing kits in human and veterinary line platforms. The company’s products comprises of FTD Human Papillomavirus (HPV) high risk k …
  • Iconix Brand Group, Inc.:企業のM&A・事業提携・投資動向
    Iconix Brand Group, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Iconix Brand Group, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Localiza Rent A Car SA:企業の戦略・SWOT・財務情報
    Localiza Rent A Car SA - Strategy, SWOT and Corporate Finance Report Summary Localiza Rent A Car SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Palfinger AG (PAL):企業の財務・戦略的SWOT分析
    Palfinger AG (PAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Independent News & Media Plc:企業の戦略的SWOT分析
    Independent News & Media Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Disco Corp (6146):企業の財務・戦略的SWOT分析
    Disco Corp (6146) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Bharti Infratel Ltd:企業の戦略・SWOT・財務情報
    Bharti Infratel Ltd - Strategy, SWOT and Corporate Finance Report Summary Bharti Infratel Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆